Medtronic (NYSE:MDT – Get Free Report) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $5.42-5.50 for the period, compared to the consensus earnings per share estimate of $5.44.
Medtronic Stock Up 2.5 %
Medtronic stock opened at $87.51 on Thursday. The firm has a market cap of $112.21 billion, a price-to-earnings ratio of 31.82, a PEG ratio of 2.35 and a beta of 0.82. The stock has a fifty day simple moving average of $80.21 and a two-hundred day simple moving average of $82.30. Medtronic has a 12 month low of $68.84 and a 12 month high of $89.18. The company has a current ratio of 2.03, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.20 by $0.03. Medtronic had a return on equity of 13.47% and a net margin of 11.36%. The company had revenue of $7.97 billion during the quarter, compared to analyst estimates of $7.90 billion. During the same quarter in the previous year, the company posted $1.20 earnings per share. Medtronic’s revenue was up 3.4% compared to the same quarter last year. Equities analysts predict that Medtronic will post 5.44 EPS for the current fiscal year.
Medtronic Dividend Announcement
Analyst Upgrades and Downgrades
Several analysts recently commented on MDT shares. Oppenheimer lifted their price objective on Medtronic from $92.00 to $94.00 and gave the stock a market perform rating in a report on Wednesday. Truist Financial cut their price target on Medtronic from $88.00 to $85.00 and set a hold rating for the company in a report on Tuesday, July 16th. Wells Fargo & Company boosted their price target on Medtronic from $105.00 to $106.00 and gave the company an overweight rating in a report on Wednesday. The Goldman Sachs Group began coverage on Medtronic in a report on Thursday, May 30th. They set a sell rating and a $83.00 price target for the company. Finally, Citigroup cut their price target on Medtronic from $90.00 to $85.00 and set a neutral rating for the company in a report on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Medtronic currently has an average rating of Hold and a consensus price target of $91.50.
Check Out Our Latest Analysis on MDT
Insider Activity
In other news, CEO Geoffrey Martha sold 19,113 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $83.77, for a total value of $1,601,096.01. Following the transaction, the chief executive officer now directly owns 143,348 shares in the company, valued at $12,008,261.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.30% of the company’s stock.
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories
- Five stocks we like better than Medtronic
- Golden Cross Stocks: Pattern, Examples and Charts
- Bear Market Investing Strategies for Success
- The 3 Best Blue-Chip Stocks to Buy Now
- Flowers Foods’ Q2 Earnings: Is Now the Right Time to Invest?
- What Investors Need to Know to Beat the Market
- Top 3 Michael Burry Stock Picks to Watch in 2024
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.